Work

S1811 Mirikizumab Provides Sustained Long-Term Efficacy Up to 4 Years of Treatment for Ulcerative Colitis: Final Results From the LUCENT-3 Open-Label Extension Study

Year: 2025

Type: conference-abstract

Source: The American Journal of Gastroenterology

DOI: 10.14309/01.ajg.0001134704.09910.89

Authors: Bruce E. Sands, David B. Clemow, Geert R. D’Haens, Severine Vermeire, Peter M. Irving, Taku Kobayashi, Laurent Peyrin-Biroulet, Karen Samaan, Anil Gaur, Jerome Paulissen, Sarah Folian, Ravneet Arora, Nicholas Paquette, Richard E. Moses, Axel Dignass

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417195984

Cites:

Cited by:

Related to: